Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
ACTFAST
ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg
1 other identifier
interventional
2,080
4 countries
65
Brief Summary
Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results (ie proportion of subjects resching target)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_4
Started Jan 2003
Shorter than P25 for phase_4
65 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2003
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2004
CompletedFirst Submitted
Initial submission to the registry
February 28, 2007
CompletedFirst Posted
Study publicly available on registry
March 2, 2007
CompletedFebruary 18, 2021
February 1, 2021
1.1 years
February 28, 2007
February 17, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Proportion of subjects achieving a LDL-C target of < 100 mg/dL (2.6 mmol/L) after 12 weeks.
Secondary Outcomes (9)
Percentage of subjects achieving:
LDL-C target <100 mg/dL (<2.6 mmol/L) after 6 weeks of treatment.
Total cholesterol (TC)/HDL-C ratio target (<4.0) after 6 and 12 weeks of treatment.
Either the LDL-C <100mg/dL (<2.6 mmol/L) or TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment.
Both the LDL-C <100mg/dL (<2.6 mmol/L) and TC/HDL-C ratio (<4.0) targets after 6 and 12 weeks of treatment.
- +4 more secondary outcomes
Interventions
Eligibility Criteria
You may qualify if:
- High cholesterol blood levels (LDL-cholesterol above 100 mg/dL up to 220 mg/dL.
- Triglycerides up to 600 mg/dL.
- History of coronary artery disease (ex.: heart attack, angina), stroke, diabetes or at high risk of such events
You may not qualify if:
- Pregnancy or lactation, use of high statin doses (\>40mg) at baseline, liver or renal problems, use of other drugs that would interfere with evaluation of efficacy or cause safety problems, uncontrolled hypertension, diabetes or hypothyroidism, recent cardiac event of procedure, high baseline CPK levels
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (121)
Pfizer Investigational Site
Mississauga, Ontario, Cameroon
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Medicine Hat, Alberta, Canada
Pfizer Investigational Site
Red Deer, Alberta, Canada
Pfizer Investigational Site
Campbell River, British Columbia, Canada
Pfizer Investigational Site
Maple Ridge, British Columbia, Canada
Pfizer Investigational Site
Nanaimo, British Columbia, Canada
Pfizer Investigational Site
New Westminster, British Columbia, Canada
Pfizer Investigational Site
Richmond, British Columbia, Canada
Pfizer Investigational Site
Surrey, British Columbia, Canada
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Vernon, British Columbia, Canada
Pfizer Investigational Site
Victoria, British Columbia, Canada
Pfizer Investigational Site
Brandon, Manitoba, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Ajax, Ontario, Canada
Pfizer Investigational Site
Brampton, Ontario, Canada
Pfizer Investigational Site
Burlington, Ontario, Canada
Pfizer Investigational Site
Cambridge, Ontario, Canada
Pfizer Investigational Site
Cornwall, Ontario, Canada
Pfizer Investigational Site
Etobicoke, Ontario, Canada
Pfizer Investigational Site
Mississauga, Ontario, Canada
Pfizer Investigational Site
Niagara Falls, Ontario, Canada
Pfizer Investigational Site
North YORK, Ontario, Canada
Pfizer Investigational Site
Orillia, Ontario, Canada
Pfizer Investigational Site
Oshawa, Ontario, Canada
Pfizer Investigational Site
Rexdale, Ontario, Canada
Pfizer Investigational Site
Sarnia, Ontario, Canada
Pfizer Investigational Site
Scarborough Village, Ontario, Canada
Pfizer Investigational Site
Simcoe, Ontario, Canada
Pfizer Investigational Site
Thunder Bay, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Weston, Ontario, Canada
Pfizer Investigational Site
Whitby, Ontario, Canada
Pfizer Investigational Site
Willowdale, Ontario, Canada
Pfizer Investigational Site
Chicoutimi, Quebec, Canada
Pfizer Investigational Site
Cowansville, Quebec, Canada
Pfizer Investigational Site
Drummondville, Quebec, Canada
Pfizer Investigational Site
Joliette, Quebec, Canada
Pfizer Investigational Site
Laval, Quebec, Canada
Pfizer Investigational Site
Lévis, Quebec, Canada
Pfizer Investigational Site
Maria, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Newport, Quebec, Canada
Pfizer Investigational Site
Pointe-Claire, Quebec, Canada
Pfizer Investigational Site
Repentigny, Quebec, Canada
Pfizer Investigational Site
Saint-Hyacinthe, Quebec, Canada
Pfizer Investigational Site
Saint-Lambert, Quebec, Canada
Pfizer Investigational Site
Sainte-Foy, Quebec, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
St-georges (beauce), Quebec, Canada
Pfizer Investigational Site
Thetford-Mines, Quebec, Canada
Pfizer Investigational Site
Vaudreuil, Quebec, Canada
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada
Pfizer Investigational Site
Québec, Canada
Pfizer Investigational Site
Tricase, (LE), Italy
Pfizer Investigational Site
Vimercate, (MI), Italy
Pfizer Investigational Site
Somma Lombardo, (VA), Italy
Pfizer Investigational Site
Asti, Italy
Pfizer Investigational Site
Bari, Italy
Pfizer Investigational Site
Belluno, Italy
Pfizer Investigational Site
Bologna, Italy
Pfizer Investigational Site
Bolzano, Italy
Pfizer Investigational Site
Catania, Italy
Pfizer Investigational Site
Chieti, Italy
Pfizer Investigational Site
Ferrara, Italy
Pfizer Investigational Site
Florence, Italy
Pfizer Investigational Site
Foggia, Italy
Pfizer Investigational Site
Grosseto, Italy
Pfizer Investigational Site
Napoli, Italy
Pfizer Investigational Site
Novara, Italy
Pfizer Investigational Site
Palermo, Italy
Pfizer Investigational Site
Perugia, Italy
Pfizer Investigational Site
Potenza, Italy
Pfizer Investigational Site
Prato, Italy
Pfizer Investigational Site
Roma, Italy
Pfizer Investigational Site
Salerno, Italy
Pfizer Investigational Site
San Donato Milanese, Italy
Pfizer Investigational Site
Sassari, Italy
Pfizer Investigational Site
Savona, Italy
Pfizer Investigational Site
Siena, Italy
Pfizer Investigational Site
Torino, Italy
Pfizer Investigational Site
Venezia, Italy
Pfizer Investigational Site
L'Hospitalet de Llobregat, Barcelona, Spain
Pfizer Investigational Site
Girona, Catalonia, Spain
Pfizer Investigational Site
Galdakao, Vizcaya, Spain
Pfizer Investigational Site
Ávila, Spain
Pfizer Investigational Site
Barcelona, Spain
Pfizer Investigational Site
Granada, Spain
Pfizer Investigational Site
Huelva, Spain
Pfizer Investigational Site
Jerez de la Frontera, Spain
Pfizer Investigational Site
Madrid, Spain
Pfizer Investigational Site
Marbella, Spain
Pfizer Investigational Site
Seville, Spain
Pfizer Investigational Site
Tarragona, Spain
Pfizer Investigational Site
Valencia, Spain
Pfizer Investigational Site
Newtonabbey, Belfast, United Kingdom
Pfizer Investigational Site
Aylesbury, Buckinghamshire, United Kingdom
Pfizer Investigational Site
Ely, Cambs, United Kingdom
Pfizer Investigational Site
Peterborough, Cambs, United Kingdom
Pfizer Investigational Site
Newtonabbey, CO Antrim, United Kingdom
Pfizer Investigational Site
Hastings, EAST Sussex, United Kingdom
Pfizer Investigational Site
High Valleyfield, FIFE, United Kingdom
Pfizer Investigational Site
Rutherglen, Glasgow, United Kingdom
Pfizer Investigational Site
Leslie, FIFE, Glenrotheshire, United Kingdom
Pfizer Investigational Site
Sunbury-on-Thames, Middlesex, United Kingdom
Pfizer Investigational Site
Frome, Somerset, United Kingdom
Pfizer Investigational Site
Barry, South Glamorgan, United Kingdom
Pfizer Investigational Site
Doncaster, South Yorkshire, United Kingdom
Pfizer Investigational Site
Stairfoot, Barnsley, South Yorkshire, United Kingdom
Pfizer Investigational Site
Addlestone, Surrey, United Kingdom
Pfizer Investigational Site
East Horsley, Surrey, United Kingdom
Pfizer Investigational Site
Atherstone, Warks, United Kingdom
Pfizer Investigational Site
Balsall Common, WEST Midlands, United Kingdom
Pfizer Investigational Site
Pound Hill, Crawley, WEST Sussex, United Kingdom
Pfizer Investigational Site
Trowbridge, Wiltshire, United Kingdom
Pfizer Investigational Site
Chippenham, Wilts, United Kingdom
Pfizer Investigational Site
Sheffield, Yorkshire, United Kingdom
Pfizer Investigational Site
Bath, United Kingdom
Pfizer Investigational Site
Related Publications (2)
Gupta M, Martineau P, Tran T, Despres JP, Gaw A, de Teresa E, Farsang C, Gensini GF, Leiter LA, Blanco-Colio LM, Egido J, Langer A; ACTFAST investigators. Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. J Clin Pharmacol. 2012 Jun;52(6):850-8. doi: 10.1177/0091270011407196. Epub 2011 May 24.
PMID: 21610204DERIVEDGensini GF, Gori AM, Dilaghi B, Rostagno C, Gaw A, Blanco-Colio LM, de Teresa E, Egido J, Farsang C, Leiter LA, Martineau P, Nozza A, Langer A; Achieve Cholesterol Targets Fast withAtorvastatin Stratified Titration Investigators. Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. Int J Cardiol. 2010 Jul 23;142(3):257-64. doi: 10.1016/j.ijcard.2008.12.213. Epub 2009 Feb 12.
PMID: 19217176DERIVED
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 28, 2007
First Posted
March 2, 2007
Study Start
January 1, 2003
Primary Completion
February 1, 2004
Study Completion
February 1, 2004
Last Updated
February 18, 2021
Record last verified: 2021-02